CORDIS
EU research results

CORDIS

English EN
Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair

Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair

Objective

Disorders arising from degeneration of the intervertebral disc are an enormous clinical and financial burden on European societies. Most of the burden arises from 10% of patients who become chronically disabled. Any factor which will improve treatment of back pain sufferers or prevent development of chronic disability would have an important impact both on society and in improving quality of life of patients. Improving diagnosis is the key. At present, 85% of patients have no clear diagnosis resulting in arbitrary treatments, usually surgical, which range widely from centre to centre and are often ineffective. Without clear diagnostic criteria, treatments and preventative measures cannot be targeted effectively. Patients may be subjected to unnecessary and expensive interventions or else denied treatment which could be beneficial Scientific advances in understanding the aetiopathology of these disorders are necessary for development of objective diagnostic criteria, rational application of present treatments and development of new therapies. Genodisc aims to contribute to improvement of patient care through improving diagnosis of disc-related pathologies both by more effective utilisation of present diagnostic information and by developing novel diagnostic tools. Through these new diagnostic methods, it aims to select patients at risk of chronic low back pain and spinal stenosis. It also aims to develop criteria for selecting patients who will benefit from newly emerging biological therapies for treating disc degeneration. The scientific advances underpinning improved diagnosis will arise from genotyping carefully phenotyped patients, from research into the processes of disc degeneration and from models of how these molecular processes lead to disc failure. This research will potentially provide biomarkers which will increase diagnostic specificity and provide targets for development of drug therapies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Address

Wellington Square University Offices
Ox1 2jd Oxford

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 808 823

Administrative Contact

Stephen Conway (Mr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 164 760

UNIVERSITY OF KEELE

United Kingdom

EU Contribution

€ 238 380

UNIVERSITAET ULM

Germany

EU Contribution

€ 258 720

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 398 084

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Greece

EU Contribution

€ 198 750

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

EU Contribution

€ 375 200

BUDAI EGESZSEGKOZPONT KFT

Hungary

EU Contribution

€ 213 912

ISTITUTO ORTOPEDICO GALEAZZI

Italy

EU Contribution

€ 189 000

EDUCELL PODJETJE ZA CELICNO BIOLOGI JO DOO

Slovenia

EU Contribution

€ 151 515

Project information

Grant agreement ID: 201626

Status

Closed project

  • Start date

    1 March 2008

  • End date

    28 February 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 007 552

  • EU contribution

    € 2 997 144

Coordinated by:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom